SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Motilal Oswal Keeps Neutral Rating on Dr Reddy’s, Sets Rs 1,180 Target

Motilal Oswal says Dr Reddy’s Laboratories’ 2QFY27 revenue was in line, while EBITDA and PAT were 30% ahead of its estimates after adjusting for one-time income.

DRREDDY

Related stories